Browse studies

Find your next paid study

30 recruiting studies matching your filters

Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid (O3FA) Supplementation for Adult and Juvenile Dermatomyositis (DM/JDM)

Dermatomyositis (DM) is a rare autoimmune disease that causes muscle weakness, skin rashes, and other symptoms. Researchers think both genetic and environmenta…

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)

Estimated

~$10 – $5,625

National Institute of Environmental Health Sciences (NIEHS)NCT07111065

Environmental Risk Factors for the Anti-Synthetase Syndrome

Background: * Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researcher…

MyositisDermatomyositisPolymyositis+2 more

Estimated

~$10 – $675

National Institute of Environmental Health Sciences (NIEHS)NCT01276470

Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies

This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immune system changes and medical problems a…

DermatomyositisPolymyositisInclusion Body Myositis

Estimated

~$10 – $675

National Institute of Environmental Health Sciences (NIEHS)NCT00017914

Phase 3

A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compa…

Polymyositis, Dermatomyositis

Estimated

~$10 – $7,500

AstraZenecaNCT06455449

Phase 1

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabo…

Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03816345

Phase 2

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathi…

Idiopathic Inflammatory MyopathyDermatomyositisAnti-Synthetase Syndrome+5 more

Estimated

~$10 – $7,500

Cabaletta BioNCT06154252

Advancing Bulbar Assessment in Inclusion Body Myositis Through a Multimodal Imaging Approach

This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individual…

IBMInclusion Body MyositisMyopathy+3 more

Estimated

~$10 – $750

Johns Hopkins UniversityNCT07823101

Phase 3

A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)

The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). …

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose …

ANCA-Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)Rheumatoid Arthritis (RA)+2 more

Estimated

~$10 – $8,750

Fate TherapeuticsNCT07800871

Phase 1

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with ref…

SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus Nephritis+4 more

Estimated

~$10 – $8,750

CRISPR TherapeuticsNCT06925542

Phase 2

Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial…

DermatomyositisDermatomyositis Sine MyositisDermatomyositis With Myopathy+4 more

Estimated

~$10 – $6,250

University of MiamiNCT07486869

Phase 3

A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis …

DermatomyositisPolymyositis

Estimated

~$10 – $7,500

PfizerNCT06698796